Ewing's Sarcoma Clinical Trial
Official title:
Phase 2, Open-label, Uncontrolled, Multicenter and Prospective Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults
Verified date | July 2018 |
Source | Grupo Espanol de Investigacion en Sarcomas |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Tumors of the Ewing sarcoma family (ES) affect children, adolescents and young adults. The
reported incidence is 0.6 cases per million inhabitants every year. The peak incidence occurs
between 10 and 20 years and it is rarely diagnosed beyond 30. The ES is a severe disease with
a progression-free survival after 5 years of 60% in cases without metastasis and deadly in
the majority of patients presenting metastasis. The ES is considered a systemic disease
because, despite receiving an adequate local treatment, over 90% of patients deaths occur due
to disseminated disease. Combined therapy of surgery, radiotherapy and chemotherapy has led
to an improvement in the prognosis, achieving a survival of about 60% in most series
The MSKCC P6 protocol was developed for the treatment of high risk ES. In 2003, Kolb et al.
reported the MSKCC experience after a 4-years follow-up of 68 patients who had been included
from 1990 to 2001. Following the MSKCC P6 protocol, a survival rate of 82% was achieved in
patients without metastasis, superior to the achieved with less intensive protocols.
Following the guidelines of the MSKCC P6 protocol, in 2002 we modified the treatment schedule
to create the modified P6 protocol (MP6). GEIS intends to develop MP6 as a clinical trial,
which could provide the following potential advantages about current treatments:
1. Lower total dose of alkylating agents.
2. Early cardioprotection with dexrazoxane.
3. Radiotherapy adjusted to the initial response.
4. Pilot trial with the combination of Gemcitabine + Docetaxel for high-risk patients.
Status | Completed |
Enrollment | 43 |
Est. completion date | January 18, 2018 |
Est. primary completion date | December 20, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 40 Years |
Eligibility |
Inclusion Criteria: - Patients with Ewing's Sarcoma in which the molecular analysis has been performed in one of the 2 reference laboratories of the study and the EWS gene rearrangement has been confirmed by RT-PCR in the Hospital Sant Joan de Déu de Barcelona, or by fluorescence in situ hybridization (FISH) in the Cancer Research Center of Salamanca. - High-risk patients will be those patients with metastases, patients with primary tumor in pelvis or axial bones and patients with (micro) metastases in bone marrow detected by the molecular study. The remaining patients will be considered as standard risk. Lung nodules identified by CT-scan with diameter > 5 mm will be considered metastatic. Nodules = 5 mm will be biopsied. - Age = 40 years. - Adequate renal and hepatic function , defined as calculated creatinine clearance > 60 ml/min, creatinine, total bilirubin, AST and/or ALT < 1,5 times the upper limit of normal (ULN). - Normal cardiac function defined by echocardiography, or ejection fraction = 55%. - ECOG performance status 0 - 1 (Appendix VIII). - Informed consent form signed by parents, guardians or the patient (if over 18 years), prior to the start of treatment. - Patients of childbearing age (both men and women) must use effective contraceptive methods before study entry and during the realization of it. Effective contraceptive methods for both women and men should be extended to 6 months after stopping the treatment under study. Pregnancy must be excluded by urine test (negative pregnancy test) prior to the inclusion in the study. Exclusion Criteria: - Pregnancy or breastfeeding. - Active infection or other severe concomitant diseases. - Severe psychiatric conditions that make impossible to obtain the signed informed consent form or limit the treatment compliance. - Concurrent treatment with other experimental drugs within 30 days prior to study entry. - History of previous cancer diagnosed or treated in the past 5 years except basal cell carcinoma, cervical carcinoma in situ or superficial bladder cancer. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clínic de Barcelona | Barcelona | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | |
Spain | Hospital Vall d'Hebron | Barcelona | |
Spain | Hospital Sant Joan de Déu | Esplugues de Llobregat | |
Spain | Institut Català d'Oncologia l'Hospitalet | Hospitalet de Llobregat | |
Spain | Hospital Universitario de Canarias | La Laguna | |
Spain | Hospital Ramón y Cajal | Madrid | |
Spain | Hospital Son Espases | Palma de Mallorca | |
Spain | Hospital Universitario Miguel Servet | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
Grupo Espanol de Investigacion en Sarcomas |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival | Assessment of the progression free survival in all the patients enrolled in the study 3 years after the completion of the treatment under study. | Assessment of the progression free survival in all the patients enrolled in the study 3 years after the completion of the treatment under study. | |
Secondary | Objective response rate (ORR) | To assess the objective response rate to treatment (ORR) defined following EMEA criteria (CPMP/EWP/205/95/Rev.3/Corr.2) in high risk patients with Ewing's sarcoma treated with an early window phase of Gemcitabine + docetaxel (G + D). | two months | |
Secondary | Assessment of disease progression | To assess the disease progression, aiming to reach an index of disease progression < 20% for high risk patients during the maintenance phase with Gemcitabine + Docetaxel. | to reach an index of disease progression < 20% for high risk patients during the maintenance phase with Gemcitabine + Docetaxel. | |
Secondary | evaluate the toxicity and tolerance to the treatment Gemcitabine + Docetaxel in high risk patients, and toxicity and tolerance of mP6 treatment in all patients. | To evaluate the toxicity and tolerance to the treatment Gemcitabine + Docetaxel in high risk patients, and toxicity and tolerance of mP6 treatment in all patients. | 12 months | |
Secondary | Assessment of bone marrow condition. | Molecular diagnosis and extension study of bone marrow in all patients included in the trial. Assessment of prognostic significance of the type of translocation and the molecular effect in the bone marrow. | 24 months | |
Secondary | Study the impact of patients treated with Cardioxane in cardioprotection | Creation of a cohort of patients treated with anthracyclines at high doses and early cardioprotection with dexrazoxane (Cardioxane). Long-term study of cardioprotection in these patients compared with historical series from the P6 protocol that did not received cardioprotection. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01734863 -
Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients
|
Phase 3 | |
Completed |
NCT01674101 -
Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy
|
N/A | |
Completed |
NCT02736565 -
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
|
Phase 1 | |
Completed |
NCT00563680 -
QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
|
Phase 2 | |
Completed |
NCT00987636 -
Study in Localized and Disseminated Ewing Sarcoma
|
Phase 3 | |
Terminated |
NCT00038142 -
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
|
Phase 2 | |
Completed |
NCT02890758 -
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
|
Phase 1 | |
Completed |
NCT01583543 -
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
|
Phase 2 | |
Terminated |
NCT01313884 -
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
|
Phase 2 | |
Completed |
NCT00004853 -
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
|
Phase 1 | |
Terminated |
NCT00568464 -
Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)
|
Phase 2 | |
Completed |
NCT00001686 -
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
|
||
Completed |
NCT00492141 -
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00541411 -
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma
|
N/A | |
Completed |
NCT02063022 -
Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
|
Phase 3 | |
Completed |
NCT01598454 -
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
|
Phase 1 | |
Recruiting |
NCT03442465 -
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
|
||
Completed |
NCT02511132 -
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
|
Phase 2 | |
Completed |
NCT00923650 -
Informed Consent in Pediatric Cancer Trials
|
N/A | |
Completed |
NCT01962103 -
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
|
Phase 1/Phase 2 |